<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02035332</url>
  </required_header>
  <id_info>
    <org_study_id>CIP0001</org_study_id>
    <nct_id>NCT02035332</nct_id>
  </id_info>
  <brief_title>A Two-Phase Clinical Study of the Minerva AURORA Ablation System</brief_title>
  <official_title>A Two-Phase Clinical Study of the Minerva AURORA Ablation System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Minerva Surgical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Minerva Surgical, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the use of the Aurora Ablation System in
      reducing menstrual blood loss at 12 months post-treatment. The occurrence of adverse events
      will be assessed along with an assessment of the reduction of uterine bleeding as measured by
      a pictorial blood loss assessment chart (PBLAC) or menstrual diary.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in Menstrual Blood Loss to Normal Levels at 12-months</measure>
    <time_frame>12 Months</time_frame>
    <description>Number of subjects in whom menstrual blood loss was reduced to normal or below normal levels at 12 months, as measured by a pictorial blood loss assessment chart (PBLAC) score of &lt;=75. A score of 0 represents no bleeding.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Procedure Time</measure>
    <time_frame>Day of procedure</time_frame>
    <description>Procedure time defined as time from insertion of the Disposable Handpiece to the time of removal.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Menorrhagia Due to Benign Causes</condition>
  <arm_group>
    <arm_group_label>Aurora Treatment Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Endometrial Ablation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Aurora Endometrial Ablation System</intervention_name>
    <description>Ablation of the endometrial lining of the uterus using the Aurora System</description>
    <arm_group_label>Aurora Treatment Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Refractory menorrhagia with no definable organic cause (abnormal uterine bleeding)

          2. Female subject from age 35 to 50 years

          3. Uterine sound measurement of 6.0cm to 10.0cm (external os to internal fundus)

          4. A minimum PBLAC score of &gt;150 for 3 months prior to study enrollment; OR, A minimum
             PBLAC score &gt;150 for one month for women who either

               1. had at least 3 prior months documented failed medical therapy; or

               2. had a contraindication to medical therapy; or

               3. refused medical therapy

          5. Premenopausal at enrollment as determined by FSH measurement ≤ 40 IU/ml

          6. Not pregnant and no desire to conceive at any time

          7. Patient agrees not to use hormonal contraception or any other medical intervention for
             bleeding during the study

          8. Able to provide written informed consent using a form that has been approved by the
             reviewing IRB/EC

          9. Subject agrees to follow-up exams and data collection, including ability to accurately
             use menstrual diaries

         10. Subject who is literate or demonstrates an understanding on how to use menstrual
             diaries

        Exclusion Criteria:

          1. Pregnancy or subject with a desire to conceive

          2. Complex endometrial hyperplasia as confirmed by histology

          3. Presence of active endometritis

          4. Active pelvic inflammatory disease

          5. Active sexually transmitted disease (STD)

          6. Presence of bacteremia, sepsis, or other active systemic infection

          7. Active infection of the genitals, vagina, cervix, uterus or urinary tract at the time
             of the procedure

          8. Known/suspected gynecological malignancy within the past 5 years

          9. Known clotting defects or bleeding disorders

         10. Untreated/unevaluated cervical dysplasia

         11. Known/suspected abdominal/pelvic cancer

         12. Prior uterine surgery (except low segment cesarean section) that interrupts the
             integrity of the uterine wall (e.g., transmural myomectomy or classical cesarean
             section)

         13. Previous endometrial ablation procedure

         14. Currently on medications that could thin the myometrial muscle, such as long-term
             steroid use

         15. Currently on anticoagulants

         16. Abnormal or obstructed cavity as confirmed by hysteroscopy or SIS, specifically:

               1. Septate or bicornuate uterus or other congenital malformation of the uterine
                  cavity

               2. Pedunculated or submucosal myomas distorting the uterine cavity

               3. Polyps likely to be the cause of the subject's menorrhagia

               4. Intramural or subserosal myomas that distort the uterine cavity

         17. Presence of an intrauterine device (IUD)

         18. Subject currently on hormonal birth control therapy or unwilling to use a non-hormonal
             birth control post-ablation.

         19. Any general health condition which, in the opinion of the Investigator, could
             represent an increased risk for the subject

         20. Any subject who is participating in any other research of an investigational drug or
             device that has not yet completed the primary endpoint evaluation.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Szeged</name>
      <address>
        <city>Szeged</city>
        <state>Csongrad</state>
        <zip>6725</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kenézy Hospital</name>
      <address>
        <city>Debrecen</city>
        <state>Hajdú-Bihar</state>
        <zip>4043</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szt Imre Hospital</name>
      <address>
        <city>Budapest</city>
        <zip>1115</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hungary</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2014</study_first_submitted>
  <study_first_submitted_qc>January 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2014</study_first_posted>
  <results_first_submitted>August 21, 2015</results_first_submitted>
  <results_first_submitted_qc>September 23, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 23, 2015</results_first_posted>
  <disposition_first_submitted>August 20, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>August 20, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 22, 2014</disposition_first_posted>
  <last_update_submitted>September 23, 2015</last_update_submitted>
  <last_update_submitted_qc>September 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Excessive Uterine Bleeding</keyword>
  <keyword>Menorrhagia</keyword>
  <keyword>Endometrial Ablation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Menorrhagia</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were enrolled in the clinical trial at 3 investigational sites in Hungary from May 2011 until October 2011.</recruitment_details>
      <pre_assignment_details>23 subjects enrolled: 2 subjects excluded based on pre-procedure hysteroscopy findings and did not receive treatment, in 1 subject treatment was attempted but procedure was aborted due to the width of the uterus, the remaining 20 subjects completed study treatment. The protocol ITT population included all subjects in whom treatment was attempted.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Aurora Treatment Arm</title>
          <description>Endometrial Ablation
Aurora Endometrial Ablation System: Ablation of the endometrial lining of the uterus using the Aurora System</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21">Treatment Attempted</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="20">Treatment Completed</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20">Completed 12 Month Follow-up</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Procedure Aborted due to Uterine Width</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Enrolled Subjects</population>
      <group_list>
        <group group_id="B1">
          <title>Aurora Treatment Arm</title>
          <description>Endometrial Ablation
Aurora Endometrial Ablation System: Ablation of the endometrial lining of the uterus using the Aurora System</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="23"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.9" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>PBLAC Score (assessment of menstrual blood loss)</title>
          <description>Pictorial Blood Loss Assessment Chart (PBLAC) is a tool used to assess menstrual blood loss. The PBLAC score takes into account the number of menstrual pads and tampons used as well as amount of saturation. A score of 0 represents no bleeding. Although the PBLAC score does not yield an exact measure of blood loss, it has been found to correlate well with menstrual blood volume. A score greater than 100 is correlated with a blood loss of at least 80 mL.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="419.2" spread="152.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Reduction in Menstrual Blood Loss to Normal Levels at 12-months</title>
        <description>Number of subjects in whom menstrual blood loss was reduced to normal or below normal levels at 12 months, as measured by a pictorial blood loss assessment chart (PBLAC) score of &lt;=75. A score of 0 represents no bleeding.</description>
        <time_frame>12 Months</time_frame>
        <population>Protocol Intent-to-treat population (all subjects in whom the experimental device was attempted to be placed.)</population>
        <group_list>
          <group group_id="O1">
            <title>Aurora Treatment Arm</title>
            <description>Endometrial Ablation
Aurora Endometrial Ablation System: Ablation of the endometrial lining of the uterus using the Aurora System</description>
          </group>
        </group_list>
        <measure>
          <title>Reduction in Menstrual Blood Loss to Normal Levels at 12-months</title>
          <description>Number of subjects in whom menstrual blood loss was reduced to normal or below normal levels at 12 months, as measured by a pictorial blood loss assessment chart (PBLAC) score of &lt;=75. A score of 0 represents no bleeding.</description>
          <population>Protocol Intent-to-treat population (all subjects in whom the experimental device was attempted to be placed.)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Procedure Time</title>
        <description>Procedure time defined as time from insertion of the Disposable Handpiece to the time of removal.</description>
        <time_frame>Day of procedure</time_frame>
        <population>Subjects completing treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Aurora Treatment Arm</title>
            <description>Endometrial Ablation
Aurora Endometrial Ablation System: Ablation of the endometrial lining of the uterus using the Aurora System</description>
          </group>
        </group_list>
        <measure>
          <title>Procedure Time</title>
          <description>Procedure time defined as time from insertion of the Disposable Handpiece to the time of removal.</description>
          <population>Subjects completing treatment</population>
          <units>Minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Subjects With Amenorrhea at 12 Months</title>
        <description>Amenorrhea at 12 Months- Number of Subjects experiencing no menstrual bleeding</description>
        <time_frame>12 Months</time_frame>
        <population>Protocol Intent-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>Aurora Treatment Arm</title>
            <description>Endometrial Ablation
Aurora Endometrial Ablation System: Ablation of the endometrial lining of the uterus using the Aurora System</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects With Amenorrhea at 12 Months</title>
          <description>Amenorrhea at 12 Months- Number of Subjects experiencing no menstrual bleeding</description>
          <population>Protocol Intent-to-treat</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Aurora Treatment Arm</title>
          <description>Endometrial Ablation
Aurora Endometrial Ablation System: Ablation of the endometrial lining of the uterus using the Aurora System</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Surgery for Heart Valve Replacement</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Weakness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain-occasional in middle-back</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>pregnancy- empty sac</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Bleeding</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Pelvic Cramping (non-specific)</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Anesthesia Related</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Eugene Skalnyi, VP Medical Affairs</name_or_title>
      <organization>Minerva Surgical, Inc.</organization>
      <phone>(1) 650-284-3500</phone>
      <email>eugenes@minervasurgical.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

